US drugmaker Pfizer said on Monday that its experimental vaccine to treat Covid-19 disease is more than 90 percent effective, which represents a major victory in the battle against the epidemic.
According to the (Business Insider) website, the Pfizer and Biontech vaccine works by training the immune system to recognize a threat such as the Corona virus, and then start producing antibodies to protect itself.
While conventional vaccines are based on the idea of giving the body inactivating doses of disease, the Pfizer vaccine is designed to make the body produce the antibodies on its own.
UPDATE: We are proud to announce, along with @BioNTech_Group, that our mRNA-based vaccine candidate has, at an interim analysis, demonstrated initial evidence of efficacy against COVID19 in participants without prior evidence of SARS-CoV-2 infection.
— Pfizer Inc. (@pfizer) November 9, 2020
Basically, this technology relies on the genetic sequence of the virus, making it easier in some ways to start using it, says Chris Beyer, professor of epidemiology at Johns Hopkins College.
According to a study prepared by scientists last September and published in the medical journal “The Lancet”, vaccine developers only needed the SARS-CoV-2 genetic sequence, which became available in January, to start building a vaccine.
The vaccine uses this new technology, in which each injection contains lipid nanoparticles – fat bubbles – surrounding a strip of genetic material, and the genetic material carries a blueprint for the distinctive spiky protein that connects the surface of the coronavirus.
After being injected into the person’s arm, the fat capsule transports its load to the cells of the body, and RNA directs the material to those cells to build a protein, which stimulates the immune system to recognize the virus and prevent the occurrence of disease.
First successful data
Pfizer and its partner, the German biotechnology company Biontech, are the first pharmaceutical companies to publish successful data from a large-scale clinical trial of a vaccine for the Coronavirus.
The two companies said they had not yet found serious safety concerns and expected this month to obtain US permission to use the vaccine in emergency situations.
If they obtain the permit, the number of doses will be limited at first, and many questions remain unanswered, including the period during which the vaccine provides protection. Nevertheless, the news offers hope that other Covid-19 vaccines under development may prove effective as well.
“Today is a great day for science and humanity,” said Albert Burla, CEO of Pfizer.